Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding
NCT04878614 · University of California, Los Angeles · PHASE4 · terminated · last registry update 2023-04-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor terminated study low accrual numbers” | – | Registry record, University of California, Los Angeles |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against THRA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-09Results posted on the registry: Seattle Children's Hospital, Triostat + Placebo (NCT02320669)
- 2024-04-09Results posted on the registry: Stanford University, a drug against THRA (NCT04059237)
- 2024-04-04Results posted on the registry: Memorial Sloan Kettering Cancer Center, DNA analysis (NCT00445965)
- 2024-04-03Phase 3 first posted: AbbVie, Armour Thyroid + Levothyroxine (NCT06345339)
- 2024-03-15Results posted on the registry: Boehringer Ingelheim, R - Low dose of BI 655130 + T1 - Low dose of BI 655130 (NCT03617835)
- 2024-03-12Results posted on the registry: Boehringer Ingelheim, Lamotrigine + BI 409306 (NCT04602221)
- 2024-02-28Results posted on the registry: Takeda, Soticlestat + Soticlestat (NCT05284760)
- 2024-02-23Phase 3 first posted: King Edward Medical University, Vitamin D + Levothyroxin (NCT06276205)
- 2024-02-23Results posted on the registry: Firstkind Ltd, a drug against THRA (NCT04309110)
- 2024-01-11Phase 3 first posted: Assiut University, a drug against THRA (NCT06201364)
- 2024-01-10Results posted on the registry: Washington University School of Medicine, Thyroxine + Saline (NCT04415658)
- 2023-06-08Phase 3 first posted: Privo Technologies, PRV211 (Intraoperative Cisplatin System) + PRV111 (Cisplatin Transmucosal System) (NCT05893888)
- 2023-06-08Phase 3 first posted: Alzheimer's Prevention and Reversal Project, Inc., Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises (NCT05894954)
- 2023-01-12Phase 3 first posted: M. Medici, LT3 (liothyronine) + Placebo (NCT05682482)
- 2022-10-13Phase 3 first posted: Rare Thyroid Therapeutics International AB, Tiratricol + Placebo (NCT05579327)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision